Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics

Overview of attention for article published in Frontiers in Pharmacology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (71st percentile)

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 7,314 followers.

RT @NFBot2: Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, ... https://t.co/8CWfSCipED

RT @Sarcoma_papers: Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromato…

Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, ... https://t.co/8CWfSCipED

RT @FrontPharmacol: New Research: Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.